Viyash Scientific

₹234.67As of Sun 8 Nov 2026, 12:00 UTC

NSE:VIYASHHealthcare

Country India

PE (Fwd) 51.52

TSR 10Y CAGR 6.27%

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.98

PE TTM 58.49

TSR TTM 9.35%

Mkt cap ₹104.7B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹262

11.66%

(92.00%)

Price above Reference Value

FY23

FY24

FY25

FY26

Earnings per share₹

(4.88)

(1.44)

0.53

4.01

(399.39%)

70.44%

136.74%

656.61%

Revenue₹B

14.21

13.70

30.07

34.20

0.57%

(3.60%)

119.52%

13.75%

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

34.20

Revenue₹B

—

14.13

14.21

13.70

30.07

34.20

38.77

24.74%

13.75

Revenue growth%

—

0.57

(3.60)

119.52

13.75

13.36

7.16

—

100

51.74

Gross margin%

—

42.32

39.61

42.67

48.31

51.74

51.65

42.67

12.30

Operating margin%

—

4.10

(1.08)

1.70

5.11

12.30

12.14

4.10

5.18

Net margin%

—

2.90

(8.53)

(2.62)

0.77

5.18

4.83

0.77

58.49

P/E ratio (avg)x

—

121.1

—

344.0

49.77

55.41

121.1

—

24.65

EV/EBITx

—

85.54

—

113.6

51.99

20.98

22.04

68.76

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

4.01

EPS₹

—

1.63

(4.88)

(1.44)

0.53

4.01

4.23

25.19%

—

653.49

EPS growth%

—

(398.53)

70.56

137.10

653.49

5.55

103.83

—

100

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

Div yield (avg)%

—

Payout ratio%

—

441.9

Shares (diluted)M

—

250.7

248.5

249.9

436.1

441.9

◌441.9

15.22%

(1.33)

Buyback yield%

—

0.90

(0.57)

(74.50)

(1.33)

◌—

(0.95)

—

D/E ratiox

—

103.7

Enterprise value₹B

—

49.58

23.61

26.43

79.87

88.23

103.7

15.50%

—

LT debt₹M

—

Peers (US$1.079B)

Cap (US$)

Akums Drugs and…

1.194B

30.83x

Strides Pharma Science…

981.0M

14.94x

Procter & Gamble…

980.8M

24.30x

Jiangsu Kanion…

1.080B

22.72x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

6.597

1.937

Own earn%

—

Sh yield%

(1.33)

(0.95)

Owners

Insiders/Inst%

2.74

12.87

Short interest%

—

SBC / revenue%

1.06

Record

10Y

Profitable years

3/5

Revenue growth years

3/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

−1–12

$1 testx

—

Incr. ROIC%

—

Viyash Scientific Limited operates as a veterinary pharmaceutical Company in India, the United States, Spain, and internationally. The company provides active pharmaceutical ingredients, finished dosage formulations, analytical services, and VET formulation services for cattle and poultry. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹34.20B

24.74%

1.00×

Cost of revenue

₹16.51B

19.30%

0.84×

Operating expenses

₹13.49B

25.72%

1.03×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m